{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:12:55Z","timestamp":1648923175054},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3535","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T22:01:06Z","timestamp":1426370466000},"page":"651-655","source":"Crossref","is-referenced-by-count":3,"title":["Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D &lt;i&gt;CBFB\/MYH11&lt;\/i&gt; Developing after Exposure to Irinotecan-containing Chemoradiotherapy"],"prefix":"10.2169","volume":"54","author":[{"given":"Hiroki","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Sakashita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kurosu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kayser S, D&ouml;hner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117: 2137-2145, 2011.","DOI":"10.1182\/blood-2010-08-301713"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92: 1389-1398, 2007.","DOI":"10.3324\/haematol.11034"},{"key":"3","unstructured":"3. WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. Swerdlow SH, Campo E, Harris NL, et al, Eds. International Agency for Research on Cancer, Lyon, 2008: 127-129."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Borthakur G, Lin E, Jain N, et al. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115: 3217-3221, 2009.","DOI":"10.1002\/cncr.24367"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400: 233-255, 1998.","DOI":"10.1016\/S0167-4781(98)00139-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625, 1985.","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta\/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261: 1041-1044, 1993.","DOI":"10.1126\/science.8351518"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83: 1750-1756, 1994.","DOI":"10.1182\/blood.V83.7.1750.bloodjournal8371750"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBF beta\/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 85: 3695-3703, 1995.","DOI":"10.1182\/blood.V85.12.3695.bloodjournal85123695"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)\/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia 21: 725-731, 2007.","DOI":"10.1038\/sj.leu.2404531"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Schwind S, Edwards CG, Nicolet D, et al. inv(16)\/t(16;16) acute myeloid leukemia with non-type A <i>CBFB<\/i>-<i>MYH11<\/i> fusions associate with distinct clinical and genetic features and lack <i>KIT<\/i> mutations. Blood 121: 385-391, 2013.","DOI":"10.1182\/blood-2012-07-442772"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Quesnel B, Kantarjian H, Bjergaard JP, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 11: 2370-2379, 1993.","DOI":"10.1200\/JCO.1993.11.12.2370"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 16: 1890-1896, 1998.","DOI":"10.1200\/JCO.1998.16.5.1890"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 33: 395-400, 2002.","DOI":"10.1002\/gcc.10043"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 29: 209-230, 2006.","DOI":"10.2165\/00002018-200629030-00005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Merrouche Y, Mugneret F, Cahn JY. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Ann Oncol 17: 1025-1026, 2006.","DOI":"10.1093\/annonc\/mdj082"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nishio S, Sugiyama T, Shouji T, et al. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 106: 342-347, 2007.","DOI":"10.1016\/j.ygyno.2007.03.036"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Patel S, Liu D, Caron P, Seiter K. Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma 48: 1032-1033, 2007.","DOI":"10.1080\/10428190701216378"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 121: 170-177, 2013.","DOI":"10.1182\/blood-2012-05-431486"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sill H, Olipitz W, Zebisch A, Schulz E, Wolfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 162: 792-805, 2011.","DOI":"10.1111\/j.1476-5381.2010.01100.x"},{"key":"21","unstructured":"21. Hashimoto H, Chatterjee S, Berger NA. Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1: 369-376, 1995."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Griesinger F, Metz M, Tr&uuml;mper L, Schulz T, Haase D. Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. Lung Cancer 44: 261-265, 2004.","DOI":"10.1016\/j.lungcan.2003.11.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Numakura K, Tsuchiya N, Habuchi T, Takahashi N. Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report. Nihon Hinyokika Gakkai Zasshi 100: 580-585, 2009 (in Japanease, Abstract in English).","DOI":"10.5980\/jpnjurol.100.580"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Seymour JF, Juneja SK, Campbell LJ, et al. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 13: 1735-1740, 1999.","DOI":"10.1038\/sj.leu.2401552"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805, 2006.","DOI":"10.1038\/sj.bjc.6603011"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ducreux M, Adenis A, Pignon JP, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13\/0503 study). Eur J Cancer 49: 1236-1245, 2013.","DOI":"10.1016\/j.ejca.2012.12.011"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T21:57:03Z","timestamp":1598824623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/6\/54_54.3535\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3535","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}